SCHEMBL23980799

SCHEMBL23980799

OC(COc1c(Br)cccc1Br)c1ccc(Cl)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.36
GRM2 Q14416 1/20 0.36
SLC6A2 P23975 9/20 0.36
SLC6A4 P31645 9/20 0.36
SLC6A3 Q01959 9/20 0.36
CYP1A2 P05177 4/20 0.36
CYP3A4 P08684 4/20 0.36
CYP2D6 P10635 4/20 0.36
CYP2C9 P11712 4/20 0.36
CYP2C19 P33261 4/20 0.36
KCNH2 Q12809 3/20 0.36
S1PR1 P21453 2/20 0.34
S1PR3 Q99500 2/20 0.34
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
GPR139 Q6DWJ6 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217430 1.00 FAAH (0.36) FAAHGRM2SLC6A2SLC6A4SLC6A3
SCHEMBL23980836 0.79 AOC3 (0.40) PPARGPPARA
SCHEMBL23980839 0.79 AOC3 (0.40) PPARGPPARA
SCHEMBL17176032 0.76 SLC6A4 (0.41) FAAHSLC6A2SLC6A4SLC6A3CYP1A2
SCHEMBL23980843 0.76 LMNA (0.42)
SCHEMBL23980788 0.75 KCNH2 (0.44) GRM2KCNH2PPARGPPARAGRIN2B
SCHEMBL30217384 0.75 KCNH2 (0.44) GRM2KCNH2PPARGPPARAGRIN2B
SCHEMBL27287042 0.73 AOC3 (0.36) PPARGPPARA
SCHEMBL15260689 0.72 PYGL (0.42) FAAHSLC6A2SLC6A4SLC6A3CYP1A2
SCHEMBL30467138 0.72 PYGL (0.42) FAAHSLC6A2SLC6A4SLC6A3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR FAAH 356/4885GRM2 2912/4885SLC6A2 1795/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R FAAH 915/4885GRM2 1002/4885SLC6A2 655/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR FAAH 356/4885GRM2 2912/4885SLC6A2 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.